Global Pegfilgrastim Biosimilar Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pegfilgrastim Biosimilar Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Pegfilgrastim Biosimilar report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pegfilgrastim Biosimilar market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Mail-Order Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pegfilgrastim Biosimilar industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pegfilgrastim Biosimilar key manufacturers include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. Novartis, Mylan, Coherus BioSciences are top 3 players and held % sales share in total in 2022.
Pegfilgrastim Biosimilar can be divided into Chemotherapy Treatment and Transplantation, etc. Chemotherapy Treatment is the mainstream product in the market, accounting for % sales share globally in 2022.
Pegfilgrastim Biosimilar is widely used in various fields, such as Hospital Pharmacies, Mail-Order Pharmacies and Retail Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Pegfilgrastim Biosimilar industry development. In 2022, global % sales of Pegfilgrastim Biosimilar went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pegfilgrastim Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories
Segment by Type
Chemotherapy Treatment
Transplantation
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pegfilgrastim Biosimilar market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pegfilgrastim Biosimilar, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pegfilgrastim Biosimilar industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pegfilgrastim Biosimilar in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pegfilgrastim Biosimilar introduction, etc. Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pegfilgrastim Biosimilar market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Pegfilgrastim Biosimilar report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pegfilgrastim Biosimilar market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital Pharmacies and Mail-Order Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pegfilgrastim Biosimilar industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pegfilgrastim Biosimilar key manufacturers include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. Novartis, Mylan, Coherus BioSciences are top 3 players and held % sales share in total in 2022.
Pegfilgrastim Biosimilar can be divided into Chemotherapy Treatment and Transplantation, etc. Chemotherapy Treatment is the mainstream product in the market, accounting for % sales share globally in 2022.
Pegfilgrastim Biosimilar is widely used in various fields, such as Hospital Pharmacies, Mail-Order Pharmacies and Retail Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Pegfilgrastim Biosimilar industry development. In 2022, global % sales of Pegfilgrastim Biosimilar went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pegfilgrastim Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories
Segment by Type
Chemotherapy Treatment
Transplantation
Segment by Application
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pegfilgrastim Biosimilar market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pegfilgrastim Biosimilar, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pegfilgrastim Biosimilar industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pegfilgrastim Biosimilar in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pegfilgrastim Biosimilar introduction, etc. Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pegfilgrastim Biosimilar market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices